Press Release

Wanbury Limited Regd. Office : BSEL Tech Park, B-wing 10" Floor, Sector-30 A, Opp. Vashi Railway Station, Vashi Navi Mumbai 400 703 Maharashtra, INDIA Tel. : +91-22-6794 2222 +91-22-7196 3222 WA N B I I RY CIN L51900MH1988PLC048455 (Y Email : info@wanbury.com Website : wwwwanbury.com August 11, 2026 To To BSE Limited National Stock Exchange of India Ltd, PJ. Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street Bandra (East), Mumbai-400 001. 1 Mumbai - 400 051. Scrip Code: 524212 [ Serip Symbol: WANBURY Sub.: Press release on Un-audited Financial Results for the quarter ended 30 June, 2026 As per Regulation 30 of LODR, please find attached herewith copy of press release on Un-audited Financial Results (UFR) for the quarter and three months ended 30t June, 2026 This is for your information and record.s Thanking you. Yours faithfully, For Wanbury Limited Jitendra J. Gandhi Company Secretary Encl.: a/a. N WANBURY Press Release 11% August, 2026, Mumbai: Wanbury Limited, a pharmaceutical company with a presence in the global APl market and domestic branded formulations, has announced its financial results for the quarter ended 30* June 2026. Financial Highlights Particulars (Rs. Cr) Q1 FY27 Q1 Fy26 Y-0-Y Q4 FY26 Q-0-Q Revenue from 165.6 1632 15% 164.6 0.6% Operations Other Income 04 03 - 0.2 - EBITDA* 16.6 248 (33.0%) 30.1 (44.8%) EBITDA Margin (%) 10.0% 152% (517) bps 182% (824) bps PAT 32 135 (76.0%) 217 (85.1%) PAT Margin (%) 20% 83% (631) bps 132% (1,122) bps “Includes Other Income For the quarter ended June 30, 2026 * Revenue from operations stood at Rs. 165.6 crore, compared to Rs. 163.2 crore in Q1 FY26, registering a growth of 1.5% YoY. Growth was held back by logistics disruptions arising from the ongoing crisis in the West Asia region, which delayed a part of API export dispatches during the quarter. * Gross profit stood at Rs. 86.9 crore, compared to Rs. 882 crore in Q1 FY26. Gross margin contracted to 52.5%, from 54.0% in Q1 FY26 and 60.4% in Q4 FY26, on account of an unprecedented sudden increase in the prices of key raw materials, particularly solvents and other crude oil linked inputs, following the crisis in West Asia. * EBITDA (including other income) stood at Rs. 16.6 crore, compared to Rs. 24.8 crore in QIFY26, with an EBITDA margin at 10.0% against 15.2% in Q1FY26. * PAT stood at Rs. 3.2 crore, compared to Rs. 13.5 crore in Q1FY26, with EPS of Rs. 0.93 as against Rs. 4.12. B WANBURY Business Highlights * During the quarter, the Company completed a refinancing of its existing debt facilities, which have been taken over by Axis Finance Limited and Poonawalla Fincorp. Aggregate borrowings of Rs. 205 crore were availed from non-banking financial companies towards repayment of existing high-cost borrowings & capital expenditure. The borrowing cost of the Company reduces from 12.5% per annum to sub 10% per annum with effect from 1% July 2026, the benefit of which will be reflected in finance costs and profitability from Q2FY27 onwards. * Consequent to the refinancing, the promoters shareholding of 1,42,03,818 equity shares are now free from pledge, representing 40.65% of the Company's paid-up equity share capital and 94.51% of the Promoter Group's holding. * On the regulatory front, the Company's API manufacturing site at Tanuku, Andhra Pradesh successfully cleared the quality inspection by the Therapeutic Goods Administration (TGA), the drug regulatory agency of Australia. On receipt of the GMP' certificate, this will enable Wanbury to ship 3 additional APIs to Australia. ¢ The Patalganga facility completed the Ministry of Food and Drug Safety (MFDS), Korea inspection with zero observations, conducted between 7 and 9% April 2026, with the formal audit report and GMP certificate received during the quarter. * The Company expanded its regulatory submissions during the quarter, filing DMFs for Diphenhydramine HCl in Malaysia and Singapore, and for Paroxetine HCl in Korea and Latin America. * Subsequent to the close of the quarter, on 30 July 2026, the Company received a “No DME deficiency letter” from the office of the USFDA for multiple ANDAs referencing Wanbury's Metformin HCl API source across different formulations. The company also received Certificate of Suitability for Riveroxaben API on 31+ July 2026. « The new state of the art manufacturing block at the Andhra Pradesh site remains under validation and commercialisation for new APIs, with commercial scale-up expected to contribute to performance from the coming quarters. Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Limited, said, “QIFY27 was a quarter marked by an unprecedented increase in input costs. The ongoing crisis in West Asia drove a significant sudden increase in the prices of key raw materials, particularly solvents and other crude oil linked inputs, which led to a direct and significant contraction in gross margins during the quarter. Given the extent and timing of the increase, the entirety of this inflation could not be passed on within Q1 and will be fully passed on in Q2. EBITDA Margins for the quarter also reflect a higher enmployee cost base due to additional hiring for new growth initiatives. W WANBURY We view these pressures as transitory and specific to the input cost environment prevailing during the period. They are not indicative of the Company's normalised operating margins, and we expect gross margins and EBITDA margins to recover fully from the Q2 onwards. In addition, we expect a reduction in finance costs from Q2FY27 onwards, given that our borrowings Iave been refinanced at a lower interest rate. Operational momentum continued in the business through the quarter. We cleared regulatory inspections at both our API sites, expanded our DMF filings into new markets, and completed a refinancing that has lowered our cost of borrowing and released the pledge on the substantial majority of promoter holdings. We expect a better performance on both the topline and profitability fronts in the coming quarters, driven by the commercial scale-up of newly launched API products, recovery of margins within the existing portfolio, lower finance costs, and positive operating leverage.” About Wanbury Ltd: Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANI BURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra). The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine, Ketamine Hydrochloride and various other products in pipeline. The company's clients include some of the leading global generic players. In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynecology, orthopedics, nutraceuticals, gastro intestinal, anti- inflammatory, & analgesics. For more details on Wanbury Ltd.: hitps//wtww.wanbury.cony/ For any Investor Relations query, please contact: Jitendra J. Gandhi Smit Shah / Devyanshi Dave Sayam Pokharna Company Secretary, PR Agency, Adfactors PR IR Advisor, TIL Advisors Wanbury Limited smit.shah@adfactorspr.com Private Limited jitendra.gandhi@wanbury.com devyanshi.dave@adfactorspr.com sayam@theinvestmentlab.in N WANBURY Forward- Looking Statements: This document may contain statements, which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially JSrom the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments. EEETES